Overview

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Status:
Completed

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe Rheumatoid Arthritis (RA) that is not responding adequately to MTX.

Phase:

Phase 4

Details

Lead Sponsor:

UCB Pharma SA

Collaborator:

Parexel

Treatments:

Adalimumab
Certolizumab Pegol
Methotrexate